Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled time : 12:01 save search
Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy
Published: 2023-05-31 (Crawled : 12:01) - globenewswire.com
ENLV | $1.42 -4.05% -4.23% 92K
|
Health Technology
|
| O: -1.14%
H: 1.15%
C: 0.77%
presentation international cell meeting therapy
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
Published: 2023-05-31 (Crawled : 12:01) - biospace.com/
RCKT M | $23.44 -1.01% -1.02% 550K
|
Health Technology
|
| O: -0.24%
H: 4.42%
C: 1.6%
disease rp-a501 pharmaceuticals designation therapy
Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations
Published: 2021-02-24 (Crawled : 12:01) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 1.94%
H: 4.25%
C: 0.76%
gene therapy therapy gene therapies preclinical pre-clinical designation
Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)
Published: 2021-02-03 (Crawled : 12:01) - globenewswire.com
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 5.76%
H: 0.68%
C: -3.4%
disease gene therapies trial therapy aav9 gene therapy
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations
Published: 2021-01-28 (Crawled : 12:01) - globenewswire.com
PASG | $1.18 -7.09% -7.63% 120K
|
Health Technology
|
| O: 2.09%
H: 3.24%
C: -0.9%
gene therapy therapy fda clearance treatment fda dementia gene therapies application clearance
Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
Published: 2021-01-07 (Crawled : 12:01) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.27%
H: 0.44%
C: 0.44%
NRIX 2 d | $14.43 2.49% 2.43% 970K
|
Health Technology
|
| O: 0.52%
H: 15.42%
C: 14.2%
collaboration expansion therapy
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
Published: 2020-12-08 (Crawled : 12:01) - globenewswire.com
QURE | $4.71 0.86% 0.85% 440K
|
Health Technology
|
| O: 2.09%
H: 1.15%
C: -1.53%
therapy gene therapy trial gene therapies
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.